"Simeprevir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Oral HCV-PROTEASE INHIBITOR effective against hepatitis C virus (HCV) serine protease NS3/4A. It is used in the treatment of chronic hepatitis C (Antivirals) genotype 1 infection in adults with compensated liver disease, including CIRRHOSIS.
Descriptor ID |
D000069616
|
MeSH Number(s) |
D02.886.590.700.700 D03.633.300.819
|
Concept/Terms |
Simeprevir- Simeprevir
- N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide
TMC 435350- TMC 435350
- 435350, TMC
- TMC435350
- TMC-435350
TMC 435- TMC 435
- 435, TMC
- TMC435
- TMC-435
|
Below are MeSH descriptors whose meaning is more general than "Simeprevir".
Below are MeSH descriptors whose meaning is more specific than "Simeprevir".
This graph shows the total number of publications written about "Simeprevir" by people in this website by year, and whether "Simeprevir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 5 | 8 | 13 |
2018 | 2 | 2 | 4 |
2019 | 3 | 0 | 3 |
2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Simeprevir" by people in Profiles.
-
Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2. Phys Chem Chem Phys. 2021 Jun 09; 23(22):12549-12558.
-
Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with Mpro. J Biomol Struct Dyn. 2022 01; 40(1):325-336.
-
An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. Sci Rep. 2020 08 17; 10(1):13866.
-
Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. Life Sci. 2020 Oct 01; 258:118205.
-
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Infect Genet Evol. 2020 10; 84:104451.
-
Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection. Infect Disord Drug Targets. 2020; 20(3):389-395.
-
A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jul 01; 1120:1-7.
-
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infect Dis. 2019 Apr 02; 19(1):300.
-
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology. 2019 06; 69(6):2349-2363.
-
Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. Eur J Gastroenterol Hepatol. 2018 10; 30(10):1200-1207.